UNSPSC 51283933: Aldesulfone sodium or sulfoxone

This classification denotes a sulfonamide anti-infective agent with the molecular formula C14H16N2O6S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3C18OH4D, chemically known as methanesulfinic acid, (sulfonylbis(4,1-phenyleneimino))bis- but generally known as sulfoxone, which bears US NIH Compound Identifier 5351. Aldesulfone sodium or sulfoxone bears US NLM identifiers UMLS ID C0075606 and NCI Concept Code C72856. SMILES: C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O.

UNSPSC 51283933 Aldesulfone sodium or sulfoxone is a Commodity code whose nominal scope does not align with recent state and local procurement activity. The recent opportunities tagged under this code reflect purchases of naloxone kits, emergency medical supplies, generic pharmaceuticals, and over-the-counter products — none of which are aldesulfone sodium or sulfoxone, a sulfone compound used in leprosy and dermatitis treatment. The mismatch suggests either a tagging error in the source system or a substantial drift between the code's formal definition and actual procurement practice at the issuing bodies. State and local governments do not appear to be purchasing aldesulfone sodium or sulfoxone directly under this code.

The four recent opportunities on record originate from a county health department (Seminole County, Florida), a state health agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP, coordinated by Minnesota Department of Administration). Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with a July 26, 2023 due date; the City of Tampa issued IFB 26P00145 on March 25, 2026, for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, with a response date of March 13, 2026, and an estimated contract value of $700,000; MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 due date; and the Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs. Activity concentrates in Florida and Minnesota, with secondary involvement from Texas. The code shows no relevant recent procurement activity for the pharmaceutical compound it nominally describes.